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Since DSM-IV was published in 1994, its
approach to substance use disorders has
come under scrutiny. Strengths were iden-
tiﬁed (notably, reliability and validity of
dependence), but concerns have also
arisen. The DSM-5 Substance-Related Dis-
ordersWork Group considered these issues
and recommended revisions for DSM-5.
General concerns included whether to
retain the division into two main disorders
(dependence and abuse), whether sub-
stance use disorder criteria should be added
or removed, and whether an appropriate
substance use disorder severity indicator
could be identiﬁed. Speciﬁc issues in-
cluded possible addition of withdrawal
syndromes for several substances, align-
ment of nicotine criteria with those for
other substances, addition of biomarkers,
and inclusion of nonsubstance, behavioral
addictions.
This article presents the major issues and
evidence considered by the work group,
which included literature reviews and
extensive new data analyses. The work
group recommendations for DSM-5 revi-
sions included combining abuse and
dependence criteria into a single sub-
stance use disorder based on consistent
ﬁndings from over 200,000 study partic-
ipants, dropping legal problems and
adding craving as criteria, adding canna-
bis and caffeine withdrawal syndromes,
aligning tobacco use disorder criteria
with other substance use disorders, and
moving gambling disorders to the chap-
ter formerly reserved for substance-
related disorders. The proposed changes
overcome many problems, while further
studies will be needed to address issues for
which less data were available.
(Am J Psychiatry 2013; 170:834–851)
DSMis the standard classiﬁcation of mental disorders
used for clinical, research, policy, and reimbursement
purposes in the United States and elsewhere. It therefore
has widespread importance and inﬂuence on how disor-
ders are diagnosed, treated, and investigated. Since its ﬁrst
publication in 1952, DSM has been reviewed and revised
four times; the criteria in the last version, DSM-IV-TR, were
ﬁrst published in 1994. Since then, knowledge about
psychiatric disorders, including substance use disorders,
has advanced greatly. To take the advances into account,
a new version, DSM-5, was published in 2013. In 2007, APA
convened a multidisciplinary team of experts, the DSM-5
Substance-Related Disorders Work Group (Table 1), to
identify strengths and problems in the DSM-IV approach to
substance use disorders and to recommend improvements
for DSM-5.
Using a set of 2006 reviews (1) as a starting point, the
work group noted weaknesses, highlighted gaps in knowl-
edge, identiﬁed data sets to investigate possible solutions,
encouraged or conducted analyses to ﬁll knowledge
gaps, monitored relevant newpublications, and formulated
interim recommendations for proposed changes. The work
group elicited input on proposed changes through com-
mentary (2), expert advisers, the DSM-5 web site (receiving
520 comments on substance use disorders), and presenta-
tions at over 30 professional meetings (see Table S1 in the
data supplement that accompanies the online edition of
this article). This input led to many further analyses and
adjustments.
The revisions proposed for DSM-5 aimed to overcome
the problems identiﬁed with DSM-IV, thereby providing
an improved approach to substance use disorders. To this
end, the largest question was whether to keep abuse and
dependence as two separate disorders. This issue, which
applies across substances (alcohol, cannabis, etc.), had the
most data available. Other cross-substance issues included
the addition or removal of criteria, the diagnostic threshold,
severity indicator(s), course speciﬁers, substance-induced
disorders, and biomarkers. Substance-speciﬁc issues in-
cluded new withdrawal syndromes, the criteria for nicotine
disorders, and neurobehavioral disorder associated with pre-
natal alcohol exposure. Additional topics for consideration
involved gambling and other putative non-substance-
related behavioral addictions. This article presents the
This article is featured in this month’s AJP Audio and is an article that provides Clinical Guidance (p. A16)
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evidence that the work group considered on these issues
and the resulting recommendations.
Overarching Issues
Should Abuse and Dependence Be Kept as Two
Separate Diagnoses?
The DSM-IV criteria for substance abuse and de-
pendence are shown in Figure 1. Dependence was diag-
nosed when three or more dependence criteria were met.
Among those with no dependence diagnosis, abuse was
diagnosed when at least one abuse criterion wasmet. The
division into two disorders was guided by the concept
that the “dependence syndrome” formed one dimension
of substance problems, while social and interpersonal
consequences of heavy use formed another (3, 4). Al-
though the dimensions were assumed to be related (3, 4),
DSM-IV placed dependence above abuse in a hierarchy
by stipulating that abuse should not be diagnosed when
dependence was present. The dependence diagnosis
represented a strength of the DSM-IV approach to sub-
stance use disorders: it was consistently shown to be
highly reliable (5) and was validated with antecedent
and concurrent indicators such as treatment utilization,
impaired functioning, consumption, and comorbidity
(6–9).
However, other aspects of the DSM-IV approach were
problematic. Some issues pertained to the abuse diagnosis
and others pertained to the DSM-IV-stipulated relation-
ship of abuse to dependence. First, when diagnosed
hierarchically according to DSM-IV, the reliability and
validity of abuse were much lower than those for
dependence (5, 10). Second, by deﬁnition, a syndrome
requires more than one symptom, but nearly half of all
abuse cases were diagnosed with only one criterion, most
often hazardous use (11, 12). Third, although abuse is
often assumed to bemilder than dependence, some abuse
criteria indicate clinically severe problems (e.g., substance-
related failure to fulﬁll major responsibilities). Fourth,
common assumptions about the relationship of abuse and
dependence were shown to be incorrect in several studies
(e.g., that abuse is simply a prodromal condition to de-
pendence [13–17] and that all cases of dependence also
met criteria for abuse, a concern particularly relevant to
women and minorities [18–20]).
The problems pertaining to the DSM-IV hierarchy of
dependence over abuse also included “diagnostic orphans”
(21–24), the case of two dependence criteria and no abuse
criteria, potentially amore serious condition thanabuse but
ineligible for a diagnosis. Also, when the abuse criteria were
analyzed without regard to dependence, their test-retest
reliability improved considerably (5), suggesting that the
hierarchy, not the criteria, led to their poor reliability.
Finally, factor analyses of dependence and abuse criteria
(ignoring the DSM-IV hierarchy) showed that the criteria
formed one factor (25, 26) or two highly correlated factors
(27–34), suggesting that the criteria should be combined to
represent a single disorder.
To further investigate the relationship of abuse and
dependence criteria, thework group and other researchers
used item response theory analysis, which builds on factor
analysis, to better understand how items (in this case, the
criteria) relate to each other. Item response theory models
indicate criterion severity (inversely related to frequency:
rarely endorsed criteria are considered more severe) and
discrimination (howwell the criterion differentiates between
respondents with high and low severity of the condition).
The results from these analyses are often presented
graphically (Figure 2), where each curve represents a crite-
rion. Curves toward the right indicate criteria of greater
severity; steeper slopes indicate better discrimination (see
Table S2 in the online data supplement for more detail
about Figure 2).
TABLE 1. DSM-5 Substance-Related Disorders Work Groupa
Name Degree(s) Specialization Country
Charles O’Brien (chair)b M.D., Ph.D. Addiction psychiatry USA
Marc Auriacombe M.D. Addiction psychiatry France
Guilherme Borges Sc.D. Epidemiology Mexico
Kathleen Bucholz Ph.D. Epidemiology USA
Alan Budney Ph.D. Substance use disorder treatment, marijuana USA
Wilson Comptonb M.D., M.P.E Epidemiology, addiction psychiatry USA
Thomas Crowleyc M.D. Psychiatry USA
Bridget F. Grantb Ph.D., Ph.D. Epidemiology, biostatistics, survey research USA
Deborah S. Hasin Ph.D. Epidemiology of substance use and psychiatric disorders USA
Walter Ling M.D. Addiction psychiatry USA
Nancy M. Petry Ph.D. Substance use and gambling treatment USA
Marc Schuckit M.D. Genetics and comorbidity USA
a In addition to the scientists listed here who were members during the entire duration of the process, a list of consultants and advisers who
served on various subcommittees and contributed substantially to the discussion is contained in the ofﬁcial publication of DSM-5.
b Also a DSM-5 Task Force member.
c Co-chair, 2007–2011.
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Table 2 lists the 39 articles on the item response theory
studies that were examined or conducted by the work
group, which include over 200,000 study participants. Two
main ﬁndings arose, with similar results across substances,
countries, adults, adolescents, patients and nonpatients.
First, unidimensionality was found for all DSM-IV criteria
for abuse and dependence except legal problems, indi-
cating that dependence and the remaining abuse criteria
all indicate the same underlying condition. Second, while
severity rankings of criteria varied somewhat across studies,
abuse (red curves in Figure 2) and dependence (black curves
in Figure 2) criteria were always intermixed across the
severity spectrum, similar to the curves shown in Figure 2.
Collectively, this large body of evidence supported re-
moving the distinction between abuse and dependence.
Substance use prevalence, attitudes, and norms vary
across groups, settings, and cultures (72–74). Therefore,
the work group examined the studies listed in Table 2 in
detail for evidence of age, gender, or other cultural bias in
the DSM-5 substance use disorder criteria. Such differ-
ences are identiﬁed in an item response theory frame-
work by testing for differential item functioning (i.e.,
whether the likelihood of endorsing a criterion differs by
group after accounting for mean group differences in
the underlying substance use disorders trait). With the
exception of legal problems, the criteria did not consis-
tently indicate differential item functioning across studies.
Even where differential item functioning was found (e.g.,
see references 35 and 36), no evidence of differential
functioning of the total score (i.e., the underlying sub-
stance use disorders trait) was found. Thus, consistent
gender or cultural bias was not found, although the extent
of the changes proposed for DSM-5 criteria for substance
use disorders suggested that there would be value in
additional research using different analytic strategies to
examine whether gender, age, or ethnic bias exists in the
criteria.
DECISION: ForDSM-5, combine abuse and dependence
criteria into one disorder (Figure 1), with two additional
changes indicated below.
Should Any Diagnostic Criteria Be Dropped?
If any criteria can be removed while retaining diagnostic
accuracy, the set will be easier to use in clinical practice.
The work group considered whether two criteria could be
dropped: legal problems and tolerance.
Legal problems. Reasons to remove legal problems from
the criteria set included very low prevalence in adult
samples (31, 35, 37, 38, 41, 57) and in many (58, 61, 69)
although not all (58, 60, 68) adolescent samples, low
discrimination (28, 36, 57, 64, 66, 69, 75), poor ﬁt with other
substance use disorder criteria (28, 32, 35, 47, 51, 76), and
little added information in item response theory analyses
(28, 37, 41, 44). Some clinicians were concerned that
dropping legal problems would leave certain patients
undiagnosed, an issue speciﬁcally addressed among heavy
alcohol, cannabis, cocaine, and heroin users in metha-
done and dual-diagnosis psychiatric settings (57). None of
these patients reported substance-related legal problems
as their only criterion or “lost” a DSM-5 substance use
disorder diagnosis without this criterion. Thus, legal pro-
blems are not a useful substance use disorder criterion,
FIGURE 1. DSM-IV and DSM-5 Criteria for Substance Use Disorders
DSM-IV 
Abusea
DSM-IV 
Dependenceb
DSM-5 
Substance Use 
Disordersc
Hazardous use X – X
Social/interpersonal problems related to use X – X
Neglected major roles to use X – X
Legal problems X – –
Withdrawald – X X
Tolerance – X X
Used larger amounts/longer – X X
Repeated attempts to quit/control use – X X
Much time spent using – X X
Physical/psychological problems related to use – X X
Activities given up to use – X X
Craving – – X
≥1
criterion
≥3
criteria
≥2
criteria
a One or more abuse criteria within a 12-month period and no dependence diagnosis; applicable to all substances except nicotine, for which
DSM-IV abuse criteria were not given.
b Three or more dependence criteria within a 12-month period.
c Two or more substance use disorder criteria within a 12-month period.
d Withdrawal not included for cannabis, inhalant, and hallucinogen disorders in DSM-IV. Cannabis withdrawal added in DSM-5.
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although such problems may be an important treatment
focus in some settings.
Tolerance. Concerns about the tolerance criterion in-
cluded its operationalization, occasional poor ﬁt with
other criteria (51), occasional differential item functioning
(68), and relevance to the underlying disorder (77). How-
ever, most item response theory articles on substance
use disorder criteria (Table 2) did not ﬁnd anything
unique about tolerance relative to the other criteria.
DECISION: Drop legal problems as a DSM-5 diagnostic
criterion.
Should Any Criteria Be Added?
If new criteria increase diagnostic accuracy, the set will
be improved by their addition. The work group considered
two criteria for possible addition: craving and consumption.
Craving. Support for craving as a substance use disorder
criterion comes indirectly from behavioral (78–82), imag-
ing, pharmacology (83), and genetics studies (84). Some
believe that craving and its reduction is central to diag-
nosis and treatment (83, 85), although not all agree (86, 87).
Craving is included in the dependence criteria in ICD-10,
so adding craving to DSM-5 would increase consistency
between the nosologies.
Item response theory analyses of data from general
population and clinical samples in the United States and
elsewhere (42, 45, 47, 49, 57, 88) were used to determine
the relationship of craving to the other substance use
disorder criteria and whether its addition improved the
diagnosis. Craving was measured using questions about
a strong desire or urge to use the substance, or such
a strong desire to use that one couldn’t think of anything
else. Across studies, craving ﬁt well with the other criteria
and did not perturb their factor loadings, severity, or
discrimination. Differential item functioning was generally
no more pronounced for craving than for other criteria. In
general population samples (e.g., the blue curve in
Figure 2), craving fell within the midrange of severity
(42). In clinical samples, craving was in the mid-to-lower
FIGURE 2. Information Characteristic Curves from Item Response Theory Analysis of DSM-IV Alcohol Abuse and Dependence
Criteria, Required to Persist Across 3 Years of Follow-Upa,b
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Much time spent using
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problems related to use
Neglected major roles to use
Hazardous use
Social/interpersonal problems 
related to use
Craving
a Red curves: DSM-IV abuse criteria. Black curves: DSM-IV dependence criteria. Blue curve: Craving.
b Data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), Wave 2 (2004–2005), conducted by the National
Institute on Alcohol Abuse and Alcoholism. Participants were noninstitutionalized civilians age 20 years and older (N=34,653). The NESARC
had a multistage design and oversampled blacks, Hispanics, and young adults. Analyses were conducted with Mplus (version 6.12, Los
Angeles, Muthén & Muthén, 2011) and incorporated sample weights to adjust standard errors appropriately. See supplementary Table S2 for
more detail on this analysis.
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TABLE 2. Item Response Theory Studies on DSM-5 Substance Use Disorder Criteria
Authors, Year
(Source) Substance Country
Survey/
Samplea
Sample
Size
Diagnosis
Instrumentb
Year of
Data
Collection
Time
Frame
Unidimensionality
Shown?
Adult, general
population
Saha et al.,
2006 (35)
Alcohol USA NESARC 20,846 AUDADIS-IV 2001–2002 Current Yes
Saha et al.,
2007 (36)
Alcohol USA NESARC 20,846 AUDADIS-IV 2001–2002 Current Yes
Gillespie et al.,
2007 (31)
Cannabis USA Adult twins 1,491 SCID 1990s Lifetime Yes
Lynskey and
Agrawal,
2007 (37)
Amphetamine USA NESARC 2,025 AUDADIS-IV 2001–2002 Lifetime Yes
Cannabis USA NESARC 8,933 AUDADIS-IV 2001–2002 Lifetime Yes
Cocaine USA NESARC 2,672 AUDADIS-IV 2001–2002 Lifetime Yes
Hallucinogens USA NESARC 2,525 AUDADIS-IV 2001–2002 Lifetime Yes
Inhalants USA NESARC 728 AUDADIS-IV 2001–2002 Lifetime Yes
Opioids USA NESARC 2,060 AUDADIS-IV 2001–2002 Lifetime Yes
Sedatives USA NESARC 1,896 AUDADIS-IV 2001–2002 Lifetime Yes
Tranquilizers USA NESARC 1,487 AUDADIS-IV 2001–2002 Lifetime Yes
Compton et al.,
2009 (38)
Cannabis USA NESARC 1,603 AUDADIS-IV 2001–2002 Current Yes
McBride et al.,
2010 (39)
Nicotine USA NESARC 6,185 AUDADIS-IV 2001–2002
2004–2005
Current
and
lifetime
Yes (dependence only)
Saha et al.,
2010 (40)
Nicotine USA NESARC 7,852 AUDADIS-IV 2001–2002
2004–2005
Current Yes (dependence only)
Shmulewitz
et al.,
2010 (41)
Alcohol Israel Household 1,160 AUDADIS-IV 2007–2009 Current
and
lifetime
Yes
Keyes et al.,
2011 (42)
Alcohol USA NLAES 18,352 AUDADIS-IV 1991–1992 Current Yes
Kerridge et al.,
2011 (43)
Hallucinogens USA NESARC 2,176 AUDADIS-IV 2001–2002 Lifetime Yes
Inhalants USA NESARC 664 AUDADIS-IV 2001–2002 Lifetime Yes
Saha et al.,
2012 (44)
Amphetamine USA NESARC 1,750 AUDADIS-IV 2001–2002 Lifetime Yes
Cocaine USA NESARC 2,528 AUDADIS-IV 2001–2002 Lifetime Yes
Opioids USA NESARC 1,815 AUDADIS-IV 2001–2002 Lifetime Yes
Sedatives USA NESARC 1,609 AUDADIS-IV 2001–2002 Lifetime Yes
Tranquilizers USA NESARC 1,301 AUDADIS-IV 2001–2002 Lifetime Yes
Shmulewitz
et al., 2011
(45)
Nicotine Israel Household 727 AUDADIS-IV 2007–2009 Lifetime Yes
Wu et al.,
2011 (46)
Opioids USA NSDUH 2,824 Survey-speciﬁc
instrument
2007 Current Yes
Mewton et al.,
2011 (47)
Alcohol Australia NSMHWB 7,746 CIDI version 2.0
(modiﬁed)
1997 Current Yes
Gilder et al.,
2011 (48)
Alcohol USA American
Indians
530 SSAGA 1990s Lifetime Yes
Casey et al.,
2012 (49)
Alcohol USA NESARC 22,177 AUDADIS-IV 2004–2005 Current Yes
Wu et al.,
2012 (50)
Cannabis USA NSDUH 6,917 Survey-speciﬁc
instrument
2008 Current Yes
Adult, clinical
or mixed
Langenbucher
et al., 2004 (51)
Alcohol USA Clinical 372 CIDI–SAM 1990s Lifetime Yes
Cannabis USA Clinical 262 CIDI–SAM 1990s Lifetime Yes
Cocaine USA Clinical 225 CIDI–SAM 1990s Lifetime Yes
Wu et al.,
2009 (52)
Cocaine USA Clinical 366 DSM-IV checklist 2001–2003 Current Yes (dependence only)
Opioids USA Clinical 354 DSM-IV checklist 2001–2003 Current Yes (dependence only)
Wu et al.,
2009 (53)
Alcohol USA Clinical 462 DSM-IV checklist 2001–2003 Current Yes (dependence only)
Cannabis USA Clinical 311 DSM-IV checklist 2001–2003 Current Yes (dependence only)
Borges et al.,
2010 (54)
Alcohol Multinational ED 3,191 Adapted CIDI 1995–2003 Current Yes
Alcohol Argentina ED 662 Adapted CIDI 2001 Current Yes
Alcohol Mexico ED 547 Adapted CIDI 1996–1997 Current Yes
Alcohol Poland ED 1,098 Adapted CIDI 2002–2003 Current Yes
Alcohol USA ED 884 Adapted CIDI 1995–1996 Current Yes
continued
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TABLE 2. Item Response Theory Studies on DSM-5 Substance Use Disorder Criteria (continued)
Authors, Year
(Source) Substance Country
Survey/
Samplea
Sample
Size
Diagnosis
Instrumentb
Year of
Data
Collection
Time
Frame
Unidimensionality
Shown?
Borges et al.,
2011 (55)
Alcohol Argentina,
Mexico,
Poland, USA
ED 3,191 CIDI 1995–2003 Current Yes
McCutcheon
et al., 2011
(56)
Alcohol USA COGA 8,605 SSAGA 1989–1996 Lifetime Yes
Hasin et al.,
2012 (57)
Alcohol USA Clinical 543 PRISM 1994–1999 Current Yes
Cannabis USA Clinical 340 PRISM 1994–1999 Current Yes
Cocaine USA Clinical 483 PRISM 1994–1999 Current Yes
Opioids USA Clinical 364 PRISM 1994–1999 Current Yes
Adolescent,
general
population
Harford et al.,
2009 (58)
Alcohol USA NSDUH 133,231 Survey-speciﬁc
instrument
2002–2005 Current Yes
Strong et al.,
2009 (59)
Nicotine USA 6th–10th
graders
296 DSM-IV nicotine
dependence
measure;
mFTQ; NDSS
2003 Current Yes (dependence only)
Wu et al.,
2009 (60)
Opioids USA NSDUH 1,290 Survey-speciﬁc
instrument
2006 Current Yes
Beseler et al.,
2010 (61)
Alcohol USA College
students
353 11-item self-
report
measure
(based on
DSM criteria)
2007 Current Yes
Rose and
Dierker,
2010 (62)
Nicotine USA NSDUH 2,758 Survey-speciﬁc
instrument
1995–1998 Current Yes (dependence only)
Wu et al.,
2010 (63)
Hallucinogens USA NSDUH 1,548 Survey-speciﬁc
instrument
2004–2006 Current Yes
Hagman and
Cohn, 2011
(64)
Alcohol USA College
students
396 Survey-speciﬁc
instrument
2010 Current Yes
Mewton et al.,
2011 (65)
Alcohol Australia NSMHWB 853 CIDI version 2.0
(modiﬁed)
1997 Current Yes (“little evidence for
DSM-IV abuse/
dependence
distinction in young
adulthood”)
Piontek et al.,
2011 (66)
Cannabis France SHCDDP 3,641 M-CIDI 2008 Current Yes
Strong et al.,
2012 (67)
Nicotine USA 6th–10th
graders
and relatives
556 DSM-IV nicotine
dependence
measure;
mFTQ; NDSS
2003 Current Yes (dependence only)
Adolescent,
clinical or
mixed
Martin et al.,
2006 (28)
Alcohol USA Clinical 464 SCID 2002 Lifetime Yes
Cannabis USA Clinical 417 SCID 2002 Lifetime Yes
Gelhorn et al.,
2008 (68)
Alcohol USA Mixed 5,587 CIDI-SAM 1993–2007 Lifetime Yes
Hartman et al.,
2008 (69)
Cannabis USA Mixed 5,587 CIDI-SAM 1993–2007 Lifetime Yes
Perron et al.,
2010 (70)
Inhalants USA Clinical 279 DIS-IV 2004 Lifetime Yes
Chung et al.,
2012 (71)
Nicotine USA Clinical 471 SCID 1990–2009 Lifetime Yes
a NESARC=National Epidemiological Survey on Alcohol and Related Conditions; NLAES=National Longitudinal Alcohol Epidemiologic Survey;
NSDUH=National Survey on Drug Use and Health; NSMHWB=National Survey of Mental Health and Well-Being (Australia); ED=emergency depart-
ment; COGA=Collaborative Study on the Genetics of Alcoholism; SHCDDP=Survey on Health and Consumption during the Day of Defense Preparation.
b AUDADIS-IV=Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV; CIDI=Composite International Diagnostic Interview;
SAM=substance abuse module; SSAGA=Semi-Structured Assessment for the Genetics of Alcoholism; PRISM=Psychiatric Research Interview for
Substance and Mental Disorders; mFTQ=Modiﬁed Fagerström Tolerance Questionnaire; NDSS=Nicotine Dependence Syndrome Scale;
DIS=NIMH Diagnostic Interview Schedule.
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range of severity, likely because of high prevalence (57).
Some studies suggested that craving was redundant with
other criteria (47, 49). Using visual inspection to compare
item response theory total information curves for the
DSM-5 substance use disorder criteria with and without
craving produced inconsistent results (42, 47, 88). Using
statistical tests to compare total information curves, the
addition of craving to the dependence criteria did not
signiﬁcantly add information (45, 57). However, when
craving and the three abuse criteria were added, total
information was increased signiﬁcantly for nicotine,
alcohol, cannabis, and heroin, although not for cocaine
use disorders (45, 57). Clinicians expressed enthusiasm
about adding craving at work group presentations and on
the DSM-5 web site. In the end, while the psychometric
beneﬁt in adding a craving criterion was equivocal, the
view that craving may become a biological treatment
target (a nonpsychometric perspective) prevailed. While
awaiting the development of biological craving indicators,
clinicians and researchers can assess craving with ques-
tions like those used in the item response theory studies
(42, 45, 47, 49, 57, 88).
Consumption. The work group considered adding quantity
or frequency of consumption as a criterion. A putative
TABLE 3. Agreement Between DSM-IV Abuse/Dependence and DSM-5 Substance Use Disorders at Different Diagnostic
Thresholds
Sample (source) Sample Size Prevalence Kappa
National Epidemiologic Survey on Alcohol and
Related Conditions (6)
Drinkers, last 12 monthsa 20,836
DSM-IV alcohol 0.10
DSM-5, $2 criteria 0.11 0.73
DSM-5, $3 criteria 0.06 0.73
Collaborative studies on genetics of alcoholism
nonproband adults (56)
Drinkers, lifetime 6,673
DSM-IV alcohol 0.43
DSM-5, $2 criteria 0.43 0.80
DSM-5, $3 criteria 0.32 0.74
Cannabis users, lifetime 4,569
DSM-IV cannabis 0.35
DSM-5, $2 criteria 0.33 0.82
DSM-5, $3 criteria 0.26 0.75
Cross-national emergency departments (54)
Drinkers, last 12 monthsa 3,191
DSM-IV alcohol 0.21
DSM-5, $2 criteria 0.21 0.80
DSM-5, $3 criteria 0.15 0.79
Metropolitan clinical sample (N=663) (57)
Drinkers, last 12 monthsa 534
DSM-IV current alcohol 46.9
DSM-5, $2 criteria 48.7 0.94
DSM-5, $3 criteria 45.7 0.96
DSM-5, $4 criteria 42.8 0.92
Cannabis users, last 12 monthsa 340
DSM-IV cannabis 21.1
DSM-5, $ 2 criteria 19.6 0.85
DSM-5, $ 3 criteria 16.4 0.83
DSM-5, $ 4 criteria 13.4 0.73
Cocaine users, last 12 monthsa 483
DSM-IV cocaine 52.9
DSM-5, $2 criteria 54.5 0.93
DSM-5, $3 criteria 51.7 0.96
DSM-5, $4 criteria 48.9 0.93
Heroin users, last 12 monthsa 364
DSM-IV heroin 40.0
DSM-5, $2 criteria 41.6 0.95
DSM-5, $3 criteria 39.2 0.97
DSM-5, $4 criteria 36.5 0.96
a Any use within prior 12 months.
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criterion of ﬁve or more drinks per occasion for men and
four ormore drinks for women ﬁt well with other criteria in
the U.S. general population (36), as did at least weekly
cannabis use and daily cigarette use (38, 40). However,
issues included worsening of model ﬁt (41), unclear utility
among cannabis users (66), and lack of a uniform cross-
national alcohol indicator (54). Quantifying other illicit
drug consumption patterns is even more difﬁcult.
DECISION: Do not add consumption. Add “craving or
a strong desire or urge to use the substance” to the DSM-5
substance use disorder criteria (Figure 1). Encourage further
research on the role of craving among substance use
disorder criteria.
What Should the Diagnostic Threshold Be?
The studies in Table 2 and others (89–91) demonstrate
that the substance use disorders criteria represent a di-
mensional condition with no natural threshold. However,
a binary (yes/no) diagnostic decision is often needed.
To avoid a marked perturbation in prevalence without
justiﬁcation, the work group sought a threshold for DSM-5
substance use disorders that would yield the best
agreement with the prevalence of DSM-IV substance
abuse and dependence disorders combined. To determine
this threshold, data from general population and clinical
samples were used to compute prevalences and agree-
ment (kappa) between DSM-5 substance use disorders
and DSM-IV dependence or abuse, examining thresholds
of two or more to four or more DSM-5 criteria (Table 3). As
shown, prevalencewas very similar, and agreement (ranging
from very good to excellent) appeared maximized with the
threshold of two ormore criteria, so it was selected. Another
recent large independently conducted study further sup-
ported this threshold (92).
Concerns that the threshold of two or more criteria is too
low have been expressed in the professional (93, 94) and
lay press (95), at presentations, and on the DSM-5 web site
(e.g., that it produces an overly heterogeneous group or
that those at low severity levels are not “true” cases). These
understandable concerns were weighed against the com-
peting need to identify all cases meriting intervention,
including milder cases, for example, those presenting in
primary care. Table 3 shows that a concern that “millions
more” would be diagnosed with the DSM-5 threshold (95)
is unfounded if DSM-5 substance use disorder criteria are
assessed and decision rules are followed (rather than
assigning a substance use disorder diagnosis to any sub-
stance user). Additional concerns about the threshold
should be addressed by indicators of severity, which
clearly indicate that cases vary in severity.
An important exception to making a diagnosis of DSM-5
substance use disorder with two criteria pertains to the
supervised use of psychoactive substances for medical
purposes, including stimulants, cocaine, opioids, nitrous
oxide, sedative-hypnotic/anxiolytic drugs, and cannabis in
some jurisdictions (96, 97). These substances can produce
tolerance and withdrawal as normal physiological adapta-
tions when used appropriately for supervised medical
purposes. With a threshold of two or more criteria, these
criteria could lead to invalid substance use disorder
diagnoses even with no other criteria met. Under these
conditions, tolerance and withdrawal in the absence of
other criteria do not indicate substance use disorders and
should not be diagnosed as such.
DECISION: Set the diagnostic threshold for DSM-5
substance use disorders at two or more criteria.
How Should Severity Be Represented?
The DSM-5 Task Force asked work groups for severity
indicators of diagnoses (mild, moderate, or severe). Many
severity indicators are possible (e.g., levels of use, im-
pairment, or comorbidity), and the Substance-Related
Disorders Work Group sought a simple, parsimonious
approach. A count of the criteria themselves serves this
purpose well, since as the count increases so does the
likelihood of substance use disorder risk factors and
consequences (89–91, 98). The work group considered
weighting the count by item response theory severity
parameters, but comparing the association of weighted
and unweighted criterion counts to consumption, func-
tioning, and family history showed no advantage for
weighting (98). Furthermore, since severity parameters
differ somewhat across samples (31), no universal set of
weights exists.
DECISION: Use a criteria count (from two to 11) as an
overall severity indicator. Use number of criteria met to
indicate mild (two to three criteria), moderate (four to
ﬁve), and severe (six or more) disorders.
Speciﬁers
Physiological cases. DSM-IV included a speciﬁer for
physiological cases (i.e., those manifesting tolerance or
withdrawal, a DSM-III carryover), but the predictive value
of this speciﬁer was inconsistent (99–106). A PubMed
search indicated that this speciﬁer was unused outside of
studies investigating its validity, indicating negligible
utility.
DECISION: Eliminate the physiological speciﬁer in
DSM-5.
Course. In DSM-IV, six course speciﬁers for dependence
were provided. Four of these pertained to the time frame
and completeness of remission, and two pertained to
extenuating circumstances.
In DSM-IV, the speciﬁers for time frame and complete-
ness of remission were complex and little used. To
simplify, the work group eliminated partial remission
and divided the time frame into two categories, early and
sustained. Early remission indicates a period $3 months
but ,12 months without meeting DSM-5 substance use
disorders criteria other than craving. Three months was
selected because data indicated better outcomes for those
retained in treatment at least this long (107, 108). Sustained
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remission indicates a period lasting $12 months without
meeting DSM-5 substance use disorders criteria other than
craving. Craving is an exception because it can persist long
into remission (109, 110).
The work group noted that many clinical studies deﬁne
remission and relapse in terms of substance use per se, not
in terms of DSM criteria. The work group did not do this in
order to remain consistent with DSM-IV criteria, and
because the criteria focus on substance-related difﬁcul-
ties, not the extent of use, for the reasons discussed in the
section on adding criteria. In addition, a lack of consensus
on the level of use associated with a good outcome (111,
112) complicates substance use as a course speciﬁer for
the disorder.
The extenuating circumstance “in a controlled environ-
ment”was unchanged fromDSM-IV. DSM-IV also included
“on agonist therapy” (e.g., methadone or unspeciﬁed par-
tial agonists or agonist/antagonists). To update this cate-
gory, DSM-5 replaced it with “on maintenance therapy”
and provided speciﬁc examples.
DECISION: Deﬁne early remission as$3 to,12 months
without meeting substance use disorders criteria (except
craving) and sustained remission as $12 months without
meeting substance use disorders criteria (except craving).
Update the maintenance therapy category with examples
of agonists (e.g., methadone and buprenorphine), antag-
onists (e.g., naltrexone), and tobacco cessationmedication
(bupropion and varenicline).
Could the Deﬁnitions of Substance-Induced Mental
Disorders Be Improved?
Substance use and other mental disorders frequently
co-occur, complicating diagnosis because many symp-
toms (e.g., insomnia) are criteria for intoxication, with-
drawal syndrome, or other mental disorders. Before
DSM-IV, the nonstandardized substance-induced mental
disorder criteria had poor reliability and validity. DSM-IV
improved this (113) via standardized guidelines to differ-
entiate between “primary” and “substance-induced” men-
tal disorders. In DSM-IV, primary mental disorders were
diagnosed if they began prior to substance use or if they
persisted for more than 4 weeks after cessation of acute
withdrawal or severe intoxication. DSM-IV substance-
inducedmental disorders were deﬁned as occurring during
periods of substance intoxication or withdrawal or re-
mitting within 4 weeks thereafter. The symptoms listed for
both the relevant disorder and for substance intoxication
or withdrawal were counted toward the substance-induced
mental disorder only if they exceeded the expected severity
of intoxication or withdrawal. While severe consequences
could accompany substance-inducedmental disorders (114),
remissionwas expectedwithin days toweeks of abstinence
(115–118).
Despite these clariﬁcations, DSM-IV substance-induced
mental disorders remained diagnostically challenging
because of the absence of minimum duration and
symptom requirements and guidelines on when symp-
toms exceeded expected severity for intoxication or
withdrawal. In addition, the term “primary” was confus-
ing, implying a time sequence or diagnostic hierarchy.
Research showed that DSM-IV substance-induced mental
disorders could be diagnosed reliably (113) and validly
(119) by standardizing the procedures to determine when
symptoms were greater than expected (although these
were complex) and, importantly, by requiring the same
duration and symptom criteria as the corresponding
primary mental disorder. This evidence led to the DSM-5
Substance-Related Disorders Work Group recommenda-
tion to increase standardization of the substance-induced
mental disorder criteria by requiring that diagnoses have
the same duration and symptom criteria as the corre-
sponding primary diagnosis. However, concerns from the
other DSM-5 work groups led the Board of Trustees to
a ﬂexible approach that reversed the DSM-IV standardi-
zation. This ﬂexible approach lacked speciﬁc symptom
and duration requirements and included the addition of
disorder-speciﬁc approaches crafted by other DSM-5work
groups.
DECISIONS: 1) For a diagnosis of substance-induced
mental disorder, add a criterion that the disorder
“resembles” the full criteria for the relevant disorder. 2)
Remove the requirement that symptoms exceed expected
intoxication or withdrawal symptoms. 3) Specify that the
substance must be pharmacologically capable of pro-
ducing the psychiatric symptoms. 4) Change the name
“primary” to “independent.” 5) Adjust “substance-induced”
to “substance/medication-induced” disorders, since the
latter were included in both DSM-IV and DSM-5 criteria
but not noted in the DSM-IV title.
Could Biomarkers Be Utilized in Making Substance
Use Disorder Diagnoses?
Because of theDSM-5 Task Force interest in biomarkers,
the Substance-Related Disorders Work Group, consulting
with outside experts, considered pharmacokinetic mea-
sures of the psychoactive substances or their metabolites,
genetic markers, and brain imaging indicators of brain
structure and function.
Many measures of drugs and associated metabolites in
blood, urine, sweat, saliva, hair, and breath have well-
established sensitivity and speciﬁcity characteristics.
However, these only indicate whether a substance was
taken within a limited recent time window and thus
cannot be used to diagnose substance use disorders.
Genetic variants within alcohol metabolizing genes
(ALDH2, ADH1B, and ADH4), genes related to neurotrans-
mission such as GABRA2 (120–122), and nicotinic and
opioid receptor genes including CHRNA5 (120) and
OPRM1 (123) show replicated associations to substance
use disorders. However, these associations have small
effects or are rare inmany populations and thus cannot be
used in diagnosis. Perhaps in future editions, DSM may
842 ajp.psychiatryonline.org Am J Psychiatry 170:8, August 2013
DSM-5 CRITERIA FOR SUBSTANCE USE DISORDERS
include markers as predictors of treatment outcome (e.g.,
OPRM1 A118G and naltrexone response [124, 125])
Positron emission tomography (PET) imaging of brain
functioning indicates that dopamine is associated with
substance use (126, 127). However, measuring brain
dopamine markers involves radioligands, limiting their
use. Functional MRI (fMRI) produces structural and
functional data, but few fMRI or PET studies have
differentiated brain functioning predating and conse-
quent to onset of substance use disorders (128). Further-
more, brain imaging ﬁndings based on group differences
are not speciﬁc enough to use as diagnostic markers in
individual cases. Finally, abnormalities in brain regions
and functioning that are associated with substance use
disorders overlap with other psychiatric disorders. In sum,
biomarkers are not yet appropriate as diagnostic tests for
substance use disorders. Continued research in this area is
important.
DECISION: Do not include biomarkers.
Should Polysubstance Dependence Be Retained?
In DSM-IV, polysubstance dependence allowed diagno-
sis for multiple-substance users who failed to meet de-
pendence criteria for any one substance but had three or
more dependence criteria collectively across substances.
The category was often misunderstood as dependence on
multiple substances andwas little used (129).With the new
threshold for DSM-5 substance use disorders (two or more
criteria), the category became irrelevant.
DECISION: Eliminate polysubstance dependence.
Substance-Speciﬁc Issues
Should Cannabis, Caffeine, Inhalant, and Ecstasy
Withdrawal Disorders Be Added?
Cannabis. Cannabis withdrawal was not included in DSM-
IV because of a lack of evidence. Since then, the reliability
and validity of cannabis withdrawal has been demon-
strated in preclinical, clinical, and epidemiological studies
(126, 127, 130–135). The syndrome has a transient course
after cessation of cannabis use (135–138) and pharmaco-
logical speciﬁcity (139–141). Cannabis withdrawal is
reported by up to one-third of regular users in the general
population (131, 132, 134) and by 50%–95% of heavy users
in treatment or research studies (133, 135, 142, 143). The
clinical signiﬁcance of cannabis withdrawal is demon-
strated by use of cannabis or other substances to relieve it,
its association with difﬁculty quitting (135, 142, 144), and
worse treatment outcomes associated with greater with-
drawal severity (133, 143). In addition, in latent variable
modeling (30), adding withdrawal to other substance use
disorders criteria for cannabis improves model ﬁt.
Inhalants/hallucinogens. While some support exists for
adding withdrawal syndromes for inhalants and Ecstasy
(3,4-methylenedioxymethamphetamine) (31, 145–147), the
literature and expert consultation suggest that evidence
remains insufﬁcient to include these in DSM-5, but further
study is warranted.
Caffeine. In DSM-IV, caffeine withdrawal was included as
a research diagnosis to encourage research (148). The
accumulated evidence frompreclinical and clinical studies
since the publication of DSM-IV supports the reliability,
validity, pharmacological speciﬁcity, and clinical signiﬁ-
cance of caffeine withdrawal (149–152). Based on factor
analysis studies, the work group proposed modifying the
DSM-IV research criteria so that a diagnosis in DSM-5
would require three or more of the following symptoms: 1)
headache; 2) fatigue or drowsiness; 3) dysphoric mood or
irritability; 4) difﬁculty concentrating; and 5) nausea,
vomiting, or muscle pain/stiffness (153, 154).
DSM-IV did not include caffeine dependence despite
preclinical research literature because clinical data were
lacking (155). Relatively small-sample clinical surveys
published since then and the accumulating data on the
clinical signiﬁcance of caffeine withdrawal and depen-
dence support further consideration for a caffeine use
disorder (152, 153, 156–160), particularly given concerns
about youth energy drinkmisuse and new alcohol-caffeine
combination beverages (161, 162). However, clinical and
epidemiological studies with larger samples and more
diverse populations are needed to determine prevalence,
establish a consistent set of diagnostic criteria, and better
evaluate the clinical signiﬁcance of a caffeine use disorder.
These studies should address test-retest reliability and
antecedent, concurrent, and predictive validity (e.g.,
distress and impaired functioning).
DECISIONS: 1) Add cannabis withdrawal disorder. In-
clude withdrawal as a criterion for cannabis use disorder. 2)
Add caffeine withdrawal disorder, and include caffeine use
disorder in Section 3 (“Conditions for Further Study”).
Could the Nicotine Criteria Be Aligned With the
Diagnostic Criteria for the Other Substance Use
Disorders?
DSM-IV included nicotine dependence, but experts felt
that abuse criteria were inapplicable to nicotine (163, 164),
so thesewere not included. Nicotine dependence has good
test-retest reliability (165–167) and its criteria indicate
a unidimensional latent trait (39, 40, 62, 67, 168). Concerns
about DSM-IV-deﬁned nicotine dependence include the
utility of some criteria, the ability to predict treatment
outcome, and low prevalence in smokers (131, 163, 169).
Many studies therefore indicate nicotine dependence with
an alternative measure, the Fagerström Nicotine De-
pendence Scale (170, 171). DSM-IV and the Fagerström
scale measure somewhat different aspects of a common
underlying trait (67, 168, 172).
Because DSM-5 combines dependence and abuse,
studies addressed whether criteria for nicotine use
disorder could be aligned with other substance use
disorders (45, 71, 181), potentially also addressing the
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concerns about DSM-IV-deﬁned nicotine dependence.
Smoking researchers widely regard craving as an in-
dicator of dependence and relapse (164, 173–175). In-
creasing disapproval of smoking (176) and wider smoking
restrictions (177) suggest improved face validity of con-
tinued smoking despite interpersonal problems and
smoking-related failure to fulﬁll responsibilities as to-
bacco use disorder criteria. Smoking is highly associated
with ﬁre-related and other mortality (e.g., unintentional
injuries and vehicle crashes) (173, 178–180), suggesting
the applicability of hazardous use as a criterion for to-
bacco use disorders, parallel with hazardous use of other
substances.
To examine the alignment of criteria for tobacco use
disorder with those for other substance use disorders, an
item response theory analysis of the seven dependence
criteria, three abuse criteria, and craving was performed in
a large adult sample of smokers (45). The 11 criteria formed
a unidimensional latent trait intermixed across the severity
spectrum, signiﬁcantly increasing information over amodel
using DSM-IV nicotine dependence criteria only. Differen-
tial item functioning was found for craving and hazardous
use, but differential total score functioning was not found.
The proposed tobacco use disorder criteria (individually
and as a set) were strongly associated with a panel of
validators, including smoking quantity and smoking shortly
after awakening (181). The tobacco use disorder criteria
weremore discriminating than theDSM-IV nicotine depen-
dence criteria (181) and produced a higher prevalence than
DSM-IV criteria, addressing a DSM-IV concern (163). An
item response theory secondary analysis of 10 of the 11
criteria from adolescent and young adult substance abuse
patients (71) also revealed unidimensionality and a higher
prevalence of DSM-5 tobacco use disorder than DSM-IV
nicotine dependence (71).
DECISION: Align DSM-5 criteria for tobacco use dis-
order with criteria for the other substance use disorders.
Should Neurobehavioral Disorder Associated With
Prenatal Alcohol Exposure Be Added?
In utero alcohol exposure acts as a neurobehavioral
teratogen, with lifelong effects on CNS function and
behavior (182, 183). These effects are now known as
neurobehavioral disorder associated with prenatal alcohol
exposure. Key features include neurocognitive and behav-
ioral impairments (184) diagnosed through standardized
psychological or educational testing, caregiver/teacher
questionnaires, medical records, reports from the patient
or a knowledgeable informant, or clinician observation.
Prenatal alcohol exposure can be determined by maternal
self-report, others’ reported observations of maternal
drinking during the pregnancy, and documentation in
medical or other records.
Neurobehavioral disorder associated with prenatal alco-
hol exposure was not included in DSM-IV. The proposed
diagnostic guidelines allow this diagnosis regardless of the
facial dysmorphology required to diagnose fetal alcohol
syndrome (185). Many clinical experts support the diag-
nosis (186), and clinical need is suggested by substantial
misdiagnosis, leading to unmet treatment need (186).
However, more information is needed on this disorder
before it can be included in the main diagnosis section of
the manual.
DECISION: Include neurobehavioral disorder associ-
ated with prenatal alcohol exposure in Section 3.
Issues Not Related To Substances
Should Gambling Disorder and Other Putative
Behavioral “Addictions” Be Added to the Substance
Disorders Chapter?
Gambling. In DSM-IV, pathological gambling is in the
section entitled “Impulse-Control Disorders Not Else-
where Classiﬁed.” Pathological gambling is comorbid with
substance use disorders (187–189) and is similar to
substance use disorders in some symptom presentations
(190), biological dysfunction (191), genetic liability (192),
and treatment approaches (193–195). The work group
therefore concurred with a DSM-5 Task Force request
to move pathological gambling to the substance use
disorders chapter. The work group also recommended
other modiﬁcations (196). The name will be changed to
“Gambling Disorder” because the term pathological is
pejorative and redundant. The criterion “illegal acts to
ﬁnance gambling” was removed for the same reasons that
legal problems were removed from substance use disor-
ders (197–200; B. Grant, unpublished 2010 data). The
diagnostic threshold was reduced to four or more criteria
to improve classiﬁcation accuracy (200–203). A further
reduction in the threshold was considered, but this
greatly increased prevalence (189, 197) without evidence
for diagnostic improvement. Future research should
explore whether gambling disorder can be assessed using
criteria that are parallel to those for substance use
disorders (200).
Other non-substance-related disorders. The work group
consulted outside experts and reviewed literature on other
potential non-substance-related behaviors (e.g., Internet
gaming and shopping). This included over 200 publica-
tions on Internet gaming addiction, mostly Asian case
reports or series of young males. Despite the large
literature (204–207), no standard diagnostic criteria and
only limited data were available on prevalence, course,
or brain functioning. Therefore, research is needed to
ascertain the unique characteristics of the disorder, the
cross-cultural reliability and validity data of diagnostic
criteria, prevalence in representative samples, natural
history, and potentially associated biological factors
(196). Research on other behavioral addictions is even
more preliminary. Disorders involving sexual behaviors or
eating were handled by other work groups.
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DECISION: Include gambling disorder in the substance
use disorders section, with changes noted above. Add
Internet gaming disorder to Section 3.
Should the Name of the Chapter Be Changed?
With the addition of gambling disorder to the chapter,
a change in the title was necessary. The Board of Trustees
assigned the title “Substance-Related and Addictive Dis-
orders,” despite the DSM-5 Substance-Related Disorders
Work Group having previously approved a title (by ma-
jority but not consensus) that did not include the term
addiction. This lack of agreement over the title reﬂects an
overall tension in the ﬁeld over the terms addiction and
dependence, as seen in editorials (2, 208) advocating
addiction as a general term, reserving dependence specif-
ically for tolerance and/or withdrawal, and the more than
80 comments on these editorials that debated the pros
and cons of these terms.
Present Status and Future Directions
Since 2007, the Substance-Related Disorders Work
Group addressed many issues. The members conducted
and published analyses, and they formulated new criteria
and presented them widely for input. The DSM-5 Task
Force requested a reduction in the number of disorders
wherever possible, and the work group accomplished this.
The DSM process requires balancing many competing
needs, which is always the case when formulating new
nomenclatures. The process also entails extensive, unpaid
collaboration among a group of experts with different
backgrounds and perspectives. Scientiﬁc controversies
arose and received responses (see references 2, 47, and
209–211). Conﬂict of interest could undermine conﬁdence
in the work group’s recommendations (212), but in fact, as
monitored by APA, eight of the 12 members received no
pharmaceutical industry income over the 5 years since the
work group was convened, two received less than $1,200
and two received less than $10,000 (the APA cap) in any
single year. Some individuals assume that ﬁnancial
interests advocated directly to the work group (e.g.,
pharmaceutical companies, alcohol and tobacco in-
dustries, insurers, and providers). Actually, this never
happened. While such advocacy could have occurred
surreptitiously through unsigned DSM-5 web site com-
ments, few comments stood out as particularly inﬂuential
since they covered such a wide range of opinions. An
exception to this was the web site advocacy of nonproﬁt
groups to include neurobehavioral disorder associated
with prenatal alcohol exposure (taken into account in
forming the disorder recommendation). Ultimately, the
work group recommendations attracted considerable
interest, and the DSM-5 process stimulated much sub-
stance use disorder research that otherwise would not
have occurred.
Implementing the 11 DSM-5 substance use disorders
criteria in research and clinical assessment should be
easier than implementing the 11 DSM-IV criteria for
substance abuse and dependence, since now only one
disorder is involved instead of two hierarchical disorders.
A checklist can aid in covering all criteria. Eventually,
reducing the number of criteria to diagnose substance use
disorders will further aid implementation, which future
studies should address.
The statistical methodology used to examine the
structure of abuse and dependence criteria was state of
the art, and the data sets analyzed were large and based on
standardized diagnostic procedures with good to excellent
reliability and validity. However, these data sets, collected
several years ago, were not designed to examine the
reliability and validity of the DSM-5 substance use
disorder diagnosis. Many studies showed that DSM-IV
dependence was reliable and valid (5), suggesting that
major components of the DSM-5 substance use disorders
criteria are reliable as well. However, ﬁeld trials using
standard methodology to minimize information variance
(213) are needed to provide information on the reliability
of DSM-5 substance use disorder diagnosis that can be
directly compared with DSM-IV (214), in addition to
studies on the antecedent, concurrent, and predictive
validity of DSM-5 substance use disorders relative to
DSM-IV dependence.
The amount of data available to address the topics dis-
cussed above varied, and new studies will be needed for
some of themore speciﬁc issues. However,major concerns
regarding the combination of abuse and dependence
criteria were conclusively addressed because an astonish-
ing amount of data was available and the results were very
consistent. The recommendations for DSM-5 substance
use disorders represent the results of a lengthy and
intensive process aimed at identifying problems in DSM-
IV and resolving these through changes in DSM-5. At
the same time, the variable amount of evidence on some of
the issues points the way toward studies aimed at
further clariﬁcations and improvements in future edi-
tions of DSM.
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